The archive
Everything we’ve published.
18 pieces across news, opinion, science and field guides — every claim attributed, every gap stated.
News
The regulatory and trial cycle, read from primary sources.
The FDA Just Had Its Biggest Peptide Meeting in Years. Here's What Actually Happened.An advisory committee recommended six peptides for the compounding bulks list this July — and half the internet misread it. What the vote means, what it doesn't, and the timeline nobody quotes.Aug 31, 2026The Compounding Boom Is Over. Here's What Ended It.For two years, a drug-shortage provision let compounders legally supply the biggest weight drugs in the world. When the shortages closed, so did the lane — and the market is still absorbing it.Sep 1, 2026
Opinion
Signed editorials in the publication’s own voice.
Opinion: 'Third-Party Tested' Is the Most Abused Phrase in WellnessIt sounds like an audit. It's usually a vibe. A short editorial on the two words doing the heaviest lifting in supplement and peptide marketing — and the one question that deflates them.Aug 31, 2026Opinion: Peptides Have an Influencer Problem, and It's Not the One You ThinkThe issue isn't that people are hyping compounds. It's that the incentive structure rewards confidence over calibration — and calibration is the whole job.Sep 1, 2026Opinion: The Price Tells You Almost NothingThe same nominal compound can vary tenfold across sellers. People read that spread as a quality signal. It mostly isn't — and the reasoning cuts against cheap and expensive alike.Sep 1, 2026
Science
Class-by-class reviews of what the published literature reports.
What the Trials Actually Showed: The Incretin ClassThe GLP-1 receptor agonists are the most-studied peptide class in modern medicine. Here is what the published trials reported — numbers, models, and the gap between approved drugs and research material.Aug 28, 2026What the Research Actually Shows: The Repair PeptidesBPC-157 and thymosin beta-4 are the most talked-about peptides in recovery circles — and the gap between the published evidence and the online conversation is wider here than anywhere else.Aug 28, 2026What the Research Actually Shows: The Growth-Hormone AxisSecretagogues occupy the middle of the evidence spectrum: one approved drug, one compound with real human trials, and a family of research peptides studied mostly in models. Sorting them is the point.Aug 28, 2026The Skin Peptides: Where the Evidence Is Actually StrongestCopper peptides have fifty years of research behind them — and the strongest evidence sits in the least glamorous place. What the dermatology literature reports, and where it stops.Sep 1, 2026The Longevity Peptides: Big Promises, Small TrialsNAD⁺ precursors, mitochondrial peptides, and the telomere compounds. One has real human data on biomarkers. The others have almost nothing — and the gap is worth understanding.Sep 1, 2026The Cognitive Peptides Have a Translation ProblemSemax and Selank are prescribed medicines in Russia and unknown almost everywhere else. That gap says less about the compounds than about how evidence travels.Sep 1, 2026
Field guides
How to read certificates, chromatograms and studies for yourself.
What Is a Peptide?A structural and analytical primer: peptide bonds, why the format matters, how solid-phase synthesis works, and where purity numbers actually come from.Aug 28, 2026How to Read a Certificate of Analysis — and the Four Ways They Get FakedWhat a complete certificate contains, and the recycled, drawn, in-house and method-free failure modes to check for before trusting one.Aug 28, 2026What an HPLC Trace Shows — and What It CannotHow reversed-phase chromatography works, why purity is a relative measure, and the questions a chromatogram is structurally unable to answer.Aug 28, 2026Reading a Peptide Study: Separating Signal From NoiseA practical guide to evaluating the research behind a claim — study type, methods, dose scaling, endpoints, and where to verify a citation.Aug 28, 2026What the Community Gets Wrong About PeptidesFive specific, repeatable errors behind most confident claims: dose scaling, purity-as-identity, preclinical overreach, undefined testing, and anecdote.Aug 28, 2026Peptides, SARMs and Steroids Are Three Different ThingsThey get grouped constantly and they have almost nothing in common — different molecules, different mechanisms, different legal status. Sorting them is the first real step to understanding any of it.Sep 1, 2026What 'Research Use Only' Actually MeansThree words that appear on almost every vial in this market, widely read as a formality. They describe a real legal category — and understanding it explains most of how this industry is structured.Sep 1, 2026